Diabetes

Patients with different types of diabetes mellitus frequently show alterations in pancreatic morphology and exocrine function. PEI can therefore occur as a result of long-standing type 1 and type 2 diabetes or can be related to the development of diabetes in chronic pancreatitis.1,2

  • In a recent audit, 24% of patients with diabetes had abnormal stools (score 5 on the Bristol Stool Chart), steatorrhoea or unexplained weight loss3
  • 42% of symptomatic patients who provided a stool sample had FE-1 levels indicative of PEI3

One study examined the efficacy of Creon® in patients with tropical calculous pancreatitis, a form of chronic pancreatitis largely attributed to malnutrition that’s prevalent in India and other Afro-Asian countries in which patients present with abdominal pain, pancreatic calculi and insulin-resistant diabetes.4

After 6 months of Creon® treatment patients achieved better control of diabetes, improvement in nutrition, and overall improvement in quality of life.4 This included a significant reduction in post-prandial plasma glucose and glycosylated haemoglobin at six months vs. baseline.5

Significant reduction in post-prandial plasma glucose and glycosylated haemoglobin at baseline vs. 6 months treatment with Creon® (total dose 8,000 lipase units)4

Adapted from Mohan V et al. Int J Pancreatol. 1998.

Furthermore, these patients showed significant improvements in PEI symptoms, including the following:4

Double-blind, multi-centre, prospective, 16-week study investigating the effects of Creon® on glucose metabolism and clinical symptoms in a group of 80 insulin-treated, diabetic patients with FE-1 <100 ?g/g. Patients received 4 x Creon® 10000 capsules (n = 39) or placebo (n = 41) taken three times a day with main meals, plus two or three snacks with 2 x Creon® 10000 capsules or placebo each day.

Coeliac disease

Pancreatic exocrine insufficiency can be observed in up to 40% of patients with coeliac disease. In a prospective, longitudinal follow-up study of adult coeliac patients with PEI, 90% of patients who received pancreatin were found to have significant long-term improvements in their chronic diarrhoea. This was demonstrated by a reduction in stool frequency (p ≤ 0.0001). These patients also reported subjective improvements in both consistency and urgency, and a significant symptomatic benefit.6,7

References

  1. Hardt PD, Ewald N. Exp Diabetes Res. 2011; doi: 10.1155/2011/761950. Epub 2011 Aug 1.
  2. Ewald N et al. World J Gastroenterol. 2013; 19(42):7276-7281
  3. Cummings MH et al. Practical Diabetes 2015; 32(2): 54-58.
  4. Mohan V et al. Int J Pancreatol. 1998; 24(1): 19-22.
  5. Ewald N et al. Diabetes Metab Res Rev. 2007; 23: 386-91.
  6. Evans KE et al. Dig Dis Sci. 2010; 55: 2999-3004.
  7. Keller J et al. Gut 2005; 54(Suppl 6): 1–28
  8. Lohr JM. United Eur Gastroenterol J. 2013; 1(2): 79-83.

Patients with diabetes may have an increased risk of developing PEI, if PEI is diagnosed, these patients should be treated.8

Watch how Creon®'s unique mode of action delivers the right dose

Follow the Link  Watch now

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?

OK
NO